7.65
#P05019
3479
Background
Insulin-like growth factor 1 (IGF-1) is a small (7.65 kDa) growth factor that interacts with both the IGF-1 receptor and the insulin receptor to control cell growth and apoptosis. Release of this endocrine hormone from the liver is stimulated by growth hormone produced in the anterior pituitary (1). Circulating IGF-1 is typically bound to one of six known IGF binding proteins (IGF-BP) (2). At target cells, the IGF-1 ligand binds IGF receptors (or insulin receptors) leading to receptor autophosphorylation and activation (3). Activated receptors mediate downstream signaling pathways (including Akt and MAPK) that regulate cell proliferation, apoptosis, development and longevity. Altered expression or mutation of IGF-1 is associated with several human disorders, including type I diabetes and various forms of cancer (4). Recombinant human IGF-1 has been used in clinical trials as a potential therapeutic agent in the treatment of human diseases (5).
Endotoxin
Purity
Source / Purification
recombinant human IGF-1 expressed in E. coli
Bioactivity
ED50, as calculated by dose-dependent proliferation of murine BABC 3T3 cells, is less than 1.0 ng/ml and corresponds to a specific activity of 1 x 10 U/mg.
Background
Insulin-like growth factor 1 (IGF-1) is a small (7.65 kDa) growth factor that interacts with both the IGF-1 receptor and the insulin receptor to control cell growth and apoptosis. Release of this endocrine hormone from the liver is stimulated by growth hormone produced in the anterior pituitary (1). Circulating IGF-1 is typically bound to one of six known IGF binding proteins (IGF-BP) (2). At target cells, the IGF-1 ligand binds IGF receptors (or insulin receptors) leading to receptor autophosphorylation and activation (3). Activated receptors mediate downstream signaling pathways (including Akt and MAPK) that regulate cell proliferation, apoptosis, development and longevity. Altered expression or mutation of IGF-1 is associated with several human disorders, including type I diabetes and various forms of cancer (4). Recombinant human IGF-1 has been used in clinical trials as a potential therapeutic agent in the treatment of human diseases (5).
Background References
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。
专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
